MAXHEALTH Max Healthcare Institute Q2 FY26 results (Jul–Sep 2025) and concall
Management summary
- Max Healthcare reported a strong Q2 FY26 with network revenue growing 21% YoY to INR 2,692 crore and operating EBITDA up 23% YoY to INR 694 crore.
- Adjusted PAT increased 16% YoY to INR 406 crore, despite higher finance costs and depreciation from new units.
- The company is actively expanding capacity, with key brownfield projects nearing completion, and anticipates a significant revenue boost from CGHS rate revisions.
Source: Inve concall analysis and management guidance record.
Highlights
-
Network gross revenue grew 21% year-on-year to INR 2,692 crore, and 5% quarter-on-quarter.
-
Operating EBITDA increased 23% year-on-year to INR 694 crore, with a robust margin of 26.9%.
-
Adjusted PAT (excluding one-time tax benefit) grew 16% year-on-year to INR 406 crore.
-
Existing Units showed strong performance with 14% like-for-like revenue growth and 19% EBITDA growth.
What they filed
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| Revenue | 1,868 | 1,910 | 2,028 | 2,135 |
| EBITDA | 499 | 512 | 523 | 575 |
| Net profit | 239 | 319 | 308 | 491 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Additional revenue from CGHS revision Revenue · once fully implemented · High confidence INR 200 crore
Profitability
EBITDA flow-through from CGHS revenue Profitability · once fully implemented · High confidence 85%
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2PAT growth lagging Revenue/EBITDA Direct
You would have seen that the finance costs have gone up, and depreciation has gone up as well because we have added new hospitals in Q3 last year. And their EBITDA margins are lower. We have also taken borrowings to fund these acquisitions.
Explains the divergence in profit growth metrics, attributing it to new hospital acquisitions and associated costs.
Asked by Andrey Purushottam
ARPOB growth slowdown Direct
ARPOB growth is 3% y-o-y. But it also includes the impact of the new hospitals that we acquired and started last year. If we take that out and consider all the existing hospitals - existing hospitals mean the one that were operating before Q4 FY24 - then the ARPOB growth is aroun
Clarifies that the overall ARPOB growth is impacted by the mix of new hospitals, while existing units show stronger growth.
Asked by Andrey Purushottam
Unlock risks & concerns, Q3 FY26 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 6 risks, concerns & management red flags
- 5 watchlist triggers for Q3 FY26
- +9 more guidance targets & verbatim management quotes
- +6 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





